Knowledge Library
Pulmonary Disease Platform
WuXi AppTec offers a comprehensive platform of pulmonary disease-related services. We provide a wide panel of validated disease models, including pulmonary fibrosis, pulmonary arterial hypertension, asthma, and chronic obstructive pulmonary disease. Our experts utilize advanced technologies with fully equipped invasive and non-invasive systems, such as the pulmonary function test system.
Integrated Assay Platform Targeting HMPV Infection
Human metapneumovirus (HMPV) is a common cause of respiratory tract infections in young children, older adults, and people with weakened immune systems. HMPV is in the Pneumoviridae family along with the more commonly known respiratory syncytial virus (RSV). Currently, there is no specific antiviral therapy to treat HMPV and no vaccine to prevent HMPV. At …Read More >
Fibrosis Models in Mice and Rats
Selecting preclinical in vivo models that are reflective of clinical outcome is a key challenge in the development of new therapies to treat fibrotic diseases. To accelerate research focused on pulmonary, renal, and liver fibrosis, WuXi AppTec has established a series of in vivo models supported with anti-fibrotic efficacy data. Our platform also includes a …Read More >
AACR 2023: Comparison of two DTH models for T cell-mediated immunity
To characterize the immunity profile of the most widely used delayed-type hypersensitivity (DTH) models, WuXi AppTec scientists built 2,4-dinitrofluorobenzene (DNFB) and oxazolone-induced DTH models in both BALB/c and C57BL/6 mice with robust ear thickness as the readout. Check out our comprehensive panel of services related to autoimmune and inflammatory diseases
Large-scale synthesis of a Notum inhibitor employing a modified Sakai reaction as the key step
WuXi AppTec scientists recently contributed to a research article in the Royal Society of Chemistry describing the large-scale synthesis of a potent and selective inhibitor of Notum carboxylesterase (an enzyme that suppresses Wnt signaling pathways). By employing a modified Sakai reaction as the key step, a one-pot synthesis of this Notum inhibitor was developed, enabling …Read More >
WuXi AppTec Discovery Services
Delivering comprehensive end-to-end solutions for creating, identifying, and supporting preclinical candidates, from discovery to development, with our integrated chemistry and biology research platforms.